PCFTF Stock UPDATES Pacific Therapeutics (PCFTF) 0.0350 09/05/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 5, 2014 at 5:36 AM

Pacific Therapeutics (PCFTF) 0.0350 $PCFTF

Update on PTL-202, a Treatment for Progressive Organ Scarring, a $1.1 Billion Opportunity
ACCESSWIRE - Thu Sep 04, 7:39AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 4, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Vantage Wire Publishes Report on Pacific Therapeutics Partner Vodis Innovative Pharmaceuticals
ACCESSWIRE - Tue Sep 02, 3:32PM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Pacific Therapeutics Announces First Six Months 2014 Financial Results
ACCESSWIRE - Thu Aug 28, 5:13PM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 28, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTCBB: PCFTF) (Frankfurt: 1P3) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on erectile dysfunction and diseases of excessive scarring (fibrosis) which are $1 billion plus market opportunities.

H.C. Wainwright Initiates Coverage of Pacific Therapeutics Partner Intelgenx with a Buy Recommendation
ACCESSWIRE - Fri Aug 15, 7:48AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 15, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Vodis Pharmaceuticals and Pacific Therapeutics Agree to Share Technologies to Deliver Cannabinoid Based Therapies
ACCESSWIRE - Tue Aug 05, 8:08AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 5, 2014 / Vodis Pharmaceuticals (CSE: VP) (the "Company"

The Company is pleased to announce that it has signed a term sheet with Pacific Therapeutics ("Pacific"

agreeing to work with Pacific on the development of therapies based on extracts from cannabis plants, as previously announced by Pacific Therapeutics (PT:cse).

Pacific Therapeutics Annonuces Non-Brokered Financing
ACCESSWIRE - Tue Aug 05, 7:33AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 5, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Proactive Investor Publishes Article on Pacific Therapeutics
ACCESSWIRE - Fri Jul 25, 7:32AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 25, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Pacific Therapeutics and Vodis Innovative Pharmaceuticals Agree to Share Technologies to Deliver Cannabinoid Based Therapies
ACCESSWIRE - Thu Jul 17, 7:32AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 16, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"

The Company is pleased to announce that it has signed a term sheet with Vodis Innovative Pharmaceuticals ("Vodis"

agreeing to work with Vodis on the development of therapies based on extracts from cannabis plants.

FDA to Host Meeting on Patient Focused Drug Development for IPF
ACCESSWIRE - Wed Jul 16, 7:33AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 16, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"

The FDA registered notice in the July 8, 2014 edition of the Federal Register that on September 26, 2014, the FDA is conducting a public meeting on Patient-Focused Drug Development for idiopathic pulmonary fibrosis (IPF). FDA is interested in obtaining patient input on the impact of IPF on daily life and patients' views on currently available therapies to treat the condition.

Expiry of Chinese Patent for Erectile Dysfunction Drug Opens Additional Market Opportunity
ACCESSWIRE - Fri Jul 11, 7:35AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 11, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"

The potential market for the Company's erectile dysfunction (ED) treatment is set to grow with the expiry of the Chinese patent on the leading ED treatment set for July.

Combination Treatment for Pulmonary Fibrosis Demonstrates Significant Disease Improvement in Pre-Clinical Trial
ACCESSWIRE - Wed Jul 09, 7:35AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 9, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"

Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF), (IPF Coalition). IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer.

European Patent Office Grants Patent for PTL-202, a Treatment for Idiopathic Pulmonary Fibrosis, a $1.1 Billion Opportunity
ACCESSWIRE - Mon Jul 07, 7:32AM CDT
VANCOUVER, BC / ACCESSWIRE / July 7, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"

Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF), (IPF Coalition). IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer.

Pacific Therapeutics Plans For Clinical Trial Timely In Light of Increasing Prevalence of Pulmonary Fibrosis
ACCESSWIRE - Thu Jul 03, 1:53AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"

a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for diseases of excessive scarring (fibrosis) and erectile dysfunction commented today that ongoing preparations for its planned clinical trials appear to be timely as recent reports in the scientific literature point toward an ever-increasing incidence of Idiopathic Pulmonary Fibrosis (IPF).

Pacific Therapeutics Announces Directors Options
ACCESSWIRE - Fri Jun 27, 3:35PM CDT
VANCOUVER, BC / ACCESSWIRE / June 27, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Harcum Scholarships Transform Financial Dreams to Reality

The Power of Generosity in Education When you want to see hope packaged in action, look no further than Harcum College. It’s not just about tossing some dollars at a cause, it’s about igniting change. Scholarships at Harcum aren’t mere financial aids; they’re the lifelines some students desperately need. This National Scholarship Month, Harcum isn’t just patting...

Battery Testing Market to Reach $45 Billion by 2033

There's a gold rush happening in the battery testing market, as ambitious as any I've seen in my trading years. The market's taking off faster than a Wall Street trader on a bull market open, projected to skyrocket from $13.03 billion in 2026 to $45.06 billion by 2033. That's a hefty 19.4% compound annual growth rate, a pace that'll have big money and new players...

Oman Unveils Groundbreaking China Investment Package

Transforming Oman-China Relations Through Investment Let me tell you, this one's a hefty shake-up in the Middle East’s economic scene. Oman’s pulling in billions with its latest move, signing the biggest bundle of investment agreements in its history, all thanks to some heavy-handed diplomacy between the Sultanate’s top brass and Chinese financial muscle. We're...

Lawsuit Reveals Safety Concerns at Latin School

Allegations at the Heart of the Matter When school administrators turn a blind eye to student safety, there's bound to be fallout. Jaclyn Schwieger, a former coach at Latin School of Chicago, has hit back with a federal lawsuit. She claims her concerns about questionable behavior by male volleyball coaches were met with reprisal rather than resolution. Now she's taking...

ASSA ABLOY Moves Deeper into Brazil, Snaps Up Rometal

An Unexpected Power Play in the Aluminum Market Nov. 12, 2026, saw ASSA ABLOY make a calculated move by signing an agreement to acquire Rometal—firmly slotted in Brazil's aluminum sector. Why this gamble? Expansion, baby. You want to plant a flag in burgeoning markets; Brazil ain't a bad choice. This is more than just another deal. This is about gaining ground in a...

Xinjiang Farmer Cultivates Community Success and Skills

Growing Opportunities Beyond Tradition Zhang Xiying in Urumqi county, Xinjiang Uygur Autonomous Region, is rewriting the farming script with unflagging effort. She's not just tending to her own crops; she's nurturing a whole ecosystem of farmers who're hungry to branch out beyond traditional harvests. Picture this—a farmer turned agricultural technician, helping 19...

Revolutionary Elevator Safety Tool Hits Market

A Game Changer for Elevator Mechanics Alright, folks, let's dive into something that's making waves in the world of elevator mechanics. We're talking about an innovation that's as practical as it is simple. Based out of the steel town of Pittsburgh, a savvy inventor from East Meadow, N.Y., has cooked up an idea that's grounded in the very real-world struggles faced by...

DIR Launches WineWalrus: A New Era for Wine Lovers

The Wine Industry's Digital Splash Ah, the wonderful world of wine—a place where culture, taste, and that sweet bouquet of a well-aged vintage collide. It’s no secret that the wine industry is a cash cow, raking in more than $323 billion annually in the U.S. alone. Digital Information Resources (DIR), a savvy player in tech and media circles, decided this bubbling...

THE HONEST FARMER Risks Launch into China's Market

THE HONEST FARMER Challenges Mainland China Okay, let's tackle this little tangent in the ever-evolving saga of food exports. THE HONEST FARMER Co., Ltd., a name probably unfamiliar to many unless you're tuning into South Korea's food manufacturing scene, is stirring the pot by diving into unfamiliar waters—mainland China. They're leaning heavily on their in-house...

Halfpricesoft's Bold Move: $169 One-Time Check Printing

Breaking Away From the Subscription Cycle When's the last time you saw a price that didn't make you groan? Halfpricesoft.com seems to have stumbled upon the magic number with their $169 flat-rate deal. You might think this feels like one of those golden eggs in a nest of subscription fatigue—and you'd be right. As inflation ramps up costs, especially for small...